(Q33649438)

28 July 2017

1 reference

title

Insulin-lowering therapeutic modalities for polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

28 July 2017

1 reference

1 reference

1 reference

Ehrmann DA

1

1 reference

28 July 2017

1 June 1999

1 reference

Endocrinology and Metabolism Clinics of North America

28 July 2017

1 reference

28 July 2017

28

1 reference

28 July 2017

2

1 reference

28 July 2017

423-38, viii

1 reference

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Insulin actions on ovarian steroidogenesis are not modulated by metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and in Vivo*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Defects in beta-cell function in functional ovarian hyperandrogenism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Acanthosis nigricans and obesity: acquired and intrinsic defects in insulin action.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Insulin resistance with acanthosis nigricans: the roles of obesity and androgen excess

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970078-5

7 January 2021

10.1016/S0889-8529(05)70078-5

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10352927